- Home
- RNG vs VKTX Comparison
RNG vs VKTX Comparison
Compare RNG & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNG | VKTX |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 2013 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RNG | VKTX |
|---|---|---|
| Price | $37.04 | $35.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | $33.58 | ★ $88.00 |
| AVG Volume (30 Days) | 1.4M | ★ 2.2M |
| Earning Date | 05-07-2026 | 04-22-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | ★ 176.19 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $2,515,142,000.00 | N/A |
| Revenue This Year | $5.56 | N/A |
| Revenue Next Year | $4.56 | N/A |
| P/E Ratio | $76.99 | ★ N/A |
| Revenue Growth | ★ 4.78 | N/A |
| 52 Week Low | $21.91 | $21.23 |
| 52 Week High | $42.42 | $43.15 |
Technical Indicators
Market Signals| Indicator | RNG | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.37 | 57.77 |
| Support Level | $25.58 | $33.65 |
| Resistance Level | $39.74 | $36.23 |
| Average True Range (ATR) | 2.16 | 1.89 |
| MACD | -0.28 | 0.20 |
| Stochastic Oscillator | 66.55 | 88.73 |
Price Performance
Historical ComparisonAbout RNG RingCentral Inc.
RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.